activ
immunotherapi
aim
administ
appropri
tumor
associ
antigen
taa
way
antigenpres
cell
apc
process
present
oncolyt
effector
cell
order
erad
primari
metastas
cancer
cell
sinc
dendrit
cell
dc
profession
apc
ex
vivo
load
stimul
dc
initi
use
achiev
respons
howev
ex
vivo
gener
modif
dc
turn
laborintens
time
moneyconsum
procedur
furthermor
variabl
dc
sourc
techniqu
vector
use
taa
transfer
led
much
divers
report
taa
express
moreov
vitro
gener
dc
may
repres
suit
dc
subtyp
induct
helper
polar
antitumor
immun
respons
reduc
dc
gener
link
variabl
exploit
function
characterist
relev
dc
subtyp
natur
circul
dc
test
induct
longlast
clinic
benefit
nevertheless
isol
patientspecif
dc
remain
laborintens
expens
task
direct
target
taa
dc
situ
repres
straightforward
therefor
prefer
strategi
moreov
direct
deliveri
cargo
dc
situ
could
offer
addit
benefit
gener
scalabl
stabl
standard
vaccin
abil
tune
direct
strength
immun
respons
humor
versu
cellmedi
improv
vaccin
safeti
profil
reduc
requir
dose
end
nontarget
cell
diminish
risk
advers
event
therefor
numer
group
evalu
apc
target
vaccin
approach
remain
within
scope
review
limit
discuss
apc
target
strategi
evalu
framework
antitumor
immunotherapi
dc
character
stellat
cytoplasm
protrus
endow
elong
contact
surfac
antigen
captur
present
special
antigen
captur
featur
evidenc
notion
sever
antigen
uptak
receptor
dc
inhibitori
receptor
next
uniqu
capabl
crosspres
exogen
antigen
cell
upon
uptak
drain
antigen
antigen
handov
migratori
dc
acquir
peptidemhc
complex
also
known
crossdress
oppos
macrophag
abl
regul
process
capac
degrad
engulf
cargo
slowli
control
lysosom
degrad
order
preserv
peptid
tcell
recognit
next
presenc
mhcpeptid
complex
dc
also
express
sever
costimulatori
molecul
order
properli
guid
naiv
cell
next
structur
featur
dc
remark
function
plastic
accomplish
strateg
posit
bodi
barrier
organ
entri
port
one
hand
abl
induc
immun
respons
invad
pathogen
nonself
hand
dc
induc
toler
order
avoid
unwant
immun
reaction
autoantigen
self
gener
immatur
dc
effici
take
pathogen
apoptot
cell
particul
antigen
environ
receptormedi
phagocytosi
macropinocytosi
caveola
clathrinmedi
endocytosi
furthermor
remain
tissueresid
high
turnov
rate
mhciipeptid
complex
lack
tcell
stimulatori
molecul
henc
induc
tcell
energi
instead
tcell
activ
upon
dct
cell
interact
contrast
activ
dc
consid
immunogen
upon
matur
lose
endo
phagocyt
receptor
slow
antigen
captur
process
rate
upregul
signal
two
molecul
like
costimulatori
molecul
eg
signal
three
molecul
eg
stimul
polar
naiv
cell
respect
furthermor
acquir
higher
cellular
motil
upregul
cc
chemokin
receptor
type
enabl
dc
migrat
peripheri
tcell
area
drain
lymphoid
tissu
howev
view
immatur
dc
induc
toler
matur
dc
induc
immun
simplifi
demonstr
matur
dc
contribut
tcell
toler
well
suggest
matur
trigger
dictat
immun
function
dc
third
reason
dc
sophist
apc
reflect
complex
matur
signal
detect
respond
import
pathway
known
today
encount
microbi
agent
trigger
surfac
intracellular
toll
like
receptor
tlr
c
type
lectin
receptor
clr
retino
acidinduc
gene
rigi
nucleotidebind
oligomer
domain
nod
like
receptor
direct
interact
cell
b
cell
cell
natur
killer
nk
cell
natur
killer
nkt
cell
stimul
cellular
product
like
ligand
product
die
cell
name
damageassoci
molecular
pattern
damp
like
heat
shock
protein
high
mobilitygroup
box
protein
uric
acid
distinct
antigen
abl
trigger
dc
matur
via
one
pathway
combin
serv
fingerprint
trigger
specif
set
receptor
subsequ
complex
signal
network
activ
cooper
integr
final
converg
upregul
distinct
transcript
factor
final
hallmark
profession
repres
differenti
anatom
locat
express
differ
marker
distinct
antigen
process
capac
variabl
respons
matur
stimuli
word
subdivis
special
subtyp
discuss
next
section
true
dc
defin
fmslike
tyrosin
kinas
ligand
depend
develop
hematopoiet
stem
cell
blood
resid
precdc
pdc
next
develop
orchestr
ifn
regulatori
basic
leucin
zipper
atflik
transcript
factor
nuclear
factor
regul
inhibitor
dna
bind
suppress
pdc
gener
differenti
transcript
factor
vrel
avian
reticuloendotheliosi
viral
oncogen
homolog
b
relb
neurogen
locu
notch
homolog
protein
recombin
signal
bind
protein
immunoglobulin
kappa
j
region
rbpj
employ
although
presum
long
time
skin
resid
lc
modc
consid
true
dc
sinc
develop
circul
monocyt
rapidli
mobil
differenti
modc
inflammatori
condit
lc
seem
origin
fetal
liver
monocyt
requir
coloni
stimul
factor
receptor
engag
via
suggest
lc
close
relat
macrophag
initi
murin
human
cdc
defin
mhcii
cell
locat
lymphoid
well
nonlymphoid
tissu
furthermor
cdc
found
lymphoid
tissu
like
bone
marrow
spleen
lymph
node
call
resid
dc
subdivid
cdc
mice
versu
cdc
human
nonlymphoid
tissu
like
skin
lung
gut
dc
call
migratori
sinc
tend
migrat
peripher
tissu
lymphoid
tissu
lymphat
mice
cdc
defin
express
human
surfac
marker
lymphoid
tissu
observ
mice
cdc
express
differ
marker
differ
anatom
locat
human
dc
dc
abundantli
present
lymphoid
nonlymphoid
tissu
liver
lung
skin
next
cdc
pdc
also
broadli
distribut
throughout
bodi
mous
pdc
specif
express
siglech
human
pdc
express
murin
modc
express
mhcii
alongsid
vari
level
human
counterpart
express
high
level
mhcii
lose
express
macrophag
coloni
stimul
factor
mcsf
receptor
note
extra
subset
human
dermal
dc
repres
cell
character
express
dcspecif
nonintegrin
dcsign
ctype
lectin
domain
famili
member
clec
lectinlik
oxid
ldl
final
murin
lc
characterist
express
langerin
c
type
lectin
local
lcspecif
organel
call
birbeck
granul
human
lc
identifi
langerin
tabl
becam
clear
murin
lymphoid
tissu
nonlymphoid
tissu
cdc
subset
well
lymphoid
tissu
nonlymphoid
tissu
dc
subset
combin
constitut
two
crossspeci
dc
lineag
respect
therefor
recent
propos
subdivid
cdc
two
main
subtyp
one
classic
type
dc
murin
human
cdc
murin
human
cdc
tabl
within
group
chemokin
emerg
import
crossspeci
marker
support
view
tradit
dc
subset
marker
inferior
identifi
supersed
cell
adhes
molecul
within
group
conserv
marker
mhciihi
signalregulatori
protein
known
pdcspecif
conserv
marker
next
conserv
marker
lc
mhcii
ecadherin
epitheli
cell
adhes
molecul
epcam
langerin
final
human
murin
modc
share
conserv
marker
mhcii
human
modc
character
murin
version
dcsign
murin
human
select
express
gene
involv
balanc
toler
crosspresent
express
high
level
mhci
processingassoci
protein
addit
possess
dual
capac
produc
larg
amount
type
ifn
make
ideal
stimul
cytotox
cell
ctl
recent
studi
underlin
intratumor
abl
facilit
adopt
ctl
control
tumor
outgrowth
contrast
mous
human
effici
present
antigen
cell
favor
polar
cell
also
appear
display
capac
crosspres
antigen
secret
high
level
suggest
potenti
key
role
promot
releas
nk
cell
therefor
also
polar
redund
may
way
allow
mass
crosspresent
human
repres
small
fraction
dc
least
blood
pdc
best
known
abil
produc
high
amount
type
ifn
respons
viral
stimuli
control
progress
viral
infect
variou
level
rest
state
howev
pdc
play
import
role
induct
toler
owe
low
express
mhc
costimulatori
molecul
compar
cdc
counterpart
howev
human
view
challeng
recent
find
metastat
melanoma
patient
receiv
intranod
inject
activ
peptid
load
pdc
effect
induc
potent
antitumor
immun
modc
special
type
subset
sinc
creat
accord
type
inflamm
gener
modc
captur
antigen
migrat
drain
lymphoid
tissu
predominantli
drive
immun
produc
respect
infect
also
produc
induc
nitric
oxid
synthas
ino
furthermor
seem
evolv
crucial
reservoir
apc
potent
emerg
backup
role
case
acut
inflamm
final
murin
epiderm
lc
atyp
apc
subset
seem
special
uptak
process
antigen
peripheri
peripher
toler
induct
especi
steadi
state
condit
addit
produc
inflamm
contrari
human
lc
describ
induc
robust
prolifer
naiv
allogen
cell
far
effici
dc
secret
promot
differenti
granzym
bperforin
ctl
moreov
appear
effici
crosspres
peptid
gener
role
lc
seem
dictat
environment
cue
rather
preimprint
behavior
summari
everi
dc
subset
function
specialti
open
excit
possibl
target
manipul
tune
immun
respons
har
subset
specif
attribut
subsequ
antitumor
vaccin
becam
question
proper
dc
activ
also
select
appropri
dc
subtyp
antigen
deliveri
socal
depoteffect
tend
retain
antigen
inject
site
increas
vaccin
uptak
apc
straightforward
way
repres
vaccin
deliveri
apc
rich
site
tumor
drain
lymph
node
spleen
exampl
deliv
taa
encod
lentivir
vector
lv
mrna
intranod
mice
stronger
therapeut
tcell
respons
induc
subcutan
deliveri
altern
vaccin
develop
way
becom
prone
accumul
lymphoid
organ
latter
exemplifi
two
differ
studi
tumor
bear
mice
nanoparticl
np
coupl
adjuv
alon
also
taa
np
accumul
tumor
drain
lymph
node
intraderm
administ
limb
ipsilater
tumor
nontumor
drain
lymph
node
administ
contralater
limb
interestingli
np
target
tumor
drain
lymph
node
tcell
distribut
within
tumor
repolar
toward
phenotyp
increas
frequenc
therapeut
antigenspecif
cell
within
tumor
observ
togeth
data
implic
tumor
drain
lymph
node
appeal
vaccin
target
solid
tumor
target
np
note
also
skin
dc
network
target
via
use
polymer
dissolv
microneedl
array
nanoencapsul
antigen
recent
intratumor
administr
antitumor
vaccin
emerg
one
hand
numer
vaccin
studi
show
induct
potent
taaspecif
tcell
respons
without
clear
therapeut
benefit
hand
tumor
microenviron
turn
manipul
system
abl
protect
tumor
cell
cytotox
attack
moreov
help
tumor
progress
noteworthi
process
regulatori
myeloid
cell
repres
myeloid
deriv
suppressor
cell
type
tumor
associ
neutrophil
subset
mast
cell
macrophag
regulatori
tumor
associ
dc
although
latter
two
could
potent
antigen
present
taa
captur
surround
tolerogen
microenviron
squeez
suppress
state
interestingli
sinc
retain
highli
plastic
phenotyp
seem
possibl
reprogram
toward
potent
antitumor
immun
stimul
apc
therefor
understand
shift
emphasi
target
apc
within
drain
lymphoid
organ
intranod
inject
lymph
node
target
np
reprogram
apc
within
tumor
microenviron
intratumor
inject
administr
base
target
straightforward
way
increas
chanc
apc
stimul
allow
apc
subtyp
specif
target
therefor
target
approach
develop
discuss
follow
paragraph
nucleic
acid
base
vaccin
administ
express
encod
taa
often
driven
strong
constitut
promot
without
enhanc
sequenc
includ
cytomegaloviru
spleen
focu
form
viru
human
polypeptid
chain
elong
phosphoglycer
kinas
ubiquitin
c
promot
although
promot
induc
strong
ubiquit
express
transgen
prone
promot
inactiv
cell
specif
promot
potent
activ
hostcel
defens
machineri
increas
potenti
risk
insert
mutagenesi
caus
enhanc
sequenc
downsid
result
develop
variou
strategi
allow
apcspecif
transgen
express
incorpor
cell
type
specif
regulatori
element
andor
promot
express
cassett
exampl
dcsign
dcstamp
langerin
hladr
mhcii
promot
howev
dc
specif
transgen
express
guarante
strong
ctl
respons
sinc
dc
specif
promot
also
appli
induc
transgen
specif
toler
furthermor
describ
tissu
specif
promot
may
still
activ
mani
differ
cell
type
state
sinc
promot
use
outsid
normal
genom
context
moreov
transcript
target
reduc
possibl
risk
insert
mutagenesi
possibl
cargo
transfer
germ
line
cell
due
conflict
outcom
research
need
done
immun
stimulatori
potenti
apc
specif
promot
driven
antitumor
vaccin
cell
entri
base
target
exploit
apc
specif
surfac
receptor
target
particular
apc
subtyp
mediat
vaccin
intern
robustli
five
main
apc
specif
receptor
famili
evalu
target
clr
famili
integrin
receptor
mhcii
molecul
immun
stimul
receptor
clr
focu
apc
target
research
mice
nonhuman
primat
human
tabl
typic
clr
recogn
carbohydr
structur
calciumdepend
manner
involv
recognit
intern
mani
glycosyl
selfantigen
pathogen
subsequ
clr
facilit
antigen
uptak
process
antigen
rout
mhci
ii
load
furthermor
depict
tabl
nonclr
noncostimulatori
molecular
target
well
costimulatori
molecul
use
restrict
antigen
deliveri
apc
one
hand
licens
apc
hand
gener
studi
regard
suit
receptor
induct
potent
antitumor
immun
remain
thu
far
contradictori
exampl
mice
immun
liposom
coupl
singl
chain
ab
fragment
scfv
latter
perform
twice
good
contrast
also
shown
target
better
target
mhcii
term
cellular
humor
immun
receptor
ligat
influenc
intracellular
vaccin
rout
receptor
select
import
function
consequ
concern
antigen
present
tcell
stimul
consequ
seem
matter
target
suitabl
dc
subtyp
also
target
appropri
dc
specif
receptor
induc
tailormad
respons
recent
three
receptor
uniqu
subset
identifi
name
interestingli
conserv
molecul
across
differ
speci
also
mechanist
involv
antigen
crosspresent
process
involv
uptak
antigen
deriv
apoptoticnecrot
cell
bind
cell
mediat
dc
tcell
adhes
promot
function
interact
nk
cell
cell
secret
sinc
crosspres
subset
current
seen
one
suitabl
target
antitumor
immunotherapi
target
vaccin
toward
one
receptor
hold
great
promis
antitumor
vaccin
besid
consider
divers
apc
specif
receptor
also
approach
target
receptor
appear
plenti
choic
base
overview
tabl
conclud
studi
target
vaccin
coupl
short
peptid
ligand
mab
carbohydr
latter
use
extens
target
dc
situ
mainli
reli
clr
bind
result
apc
dc
subtyp
specif
bind
contrari
former
three
moieti
could
gener
bind
one
particular
apc
subset
specif
receptor
advantag
short
peptid
sever
disrupt
origin
vaccin
format
target
peptid
strong
bind
affin
unlimit
specif
could
gener
via
highthroughput
librari
approach
howev
hinder
multimeris
monom
creat
fusion
product
lower
thermost
hinder
proper
intracellular
traffick
vaccin
altern
differ
kind
ligand
cytokin
growth
factor
use
addit
peptid
ligand
also
mab
deriv
evalu
apc
specif
target
gener
scfv
offer
higher
specif
short
peptid
larger
size
chanc
disrupt
process
conform
chang
mediat
membran
fusion
increas
therefor
scfv
often
link
spacer
peptid
proteas
cleavabl
peptid
permit
proper
conform
scfv
domain
target
vaccin
recent
describ
altern
abovement
target
moieti
design
ankyrin
repeat
protein
darpin
nucleic
acid
base
aptam
select
becom
highaffin
binder
kind
target
molecul
anoth
interest
altern
lie
antigen
bind
part
heavychainonli
ab
found
member
famili
camelida
antigenbind
part
compos
one
singl
variabl
region
term
vhh
nanobodi
nanobodi
uniqu
characterist
offer
mani
advantag
scfv
high
solubl
abil
refold
denatur
whilst
retain
bind
capac
clone
select
antigen
specif
nanobodi
obviat
need
construct
screen
larg
librari
nonimmunogen
fuse
protein
therefor
surpris
sever
studi
report
gener
subsequ
use
nanobodi
apc
target
exampl
hereof
develop
nanobodi
target
enabl
select
target
mmrhi
macrophag
subset
within
solid
tumor
furthermor
also
demonstr
sever
nanobodi
yet
unidentifi
target
antigen
allow
target
specif
human
murin
apc
subset
includ
dc
macrophag
select
target
cdc
case
viral
vector
sever
addit
strategi
evalu
alter
broad
infect
profil
viral
outer
membran
embed
glycoprotein
toward
apc
specif
tropism
first
strategi
repres
ration
point
domain
mutat
viral
glycoprotein
exemplifi
dcsignspecif
target
strategi
base
fact
sindbi
viru
envelop
glycoprotein
consist
fusogen
protein
cell
bind
protein
normal
bind
dcsign
receptor
next
canon
viral
receptor
heparin
sulphat
express
mani
cell
type
sinc
protein
bind
site
physic
separ
select
mutat
monom
possibl
abrog
heparin
sulfat
bind
part
leav
dcsign
bind
part
intact
pseudotyp
lv
mutat
sindbi
viru
deriv
envelop
glycoprotein
target
infect
murin
dc
direct
subcutan
administr
achiev
moreov
elicit
strong
therapeut
antigen
specif
immun
respons
besid
genet
alter
viral
surfac
also
chemic
engin
alter
bind
specif
advantag
flexibl
speed
control
modif
condit
unfortun
effect
chemic
modifi
particl
strongli
depend
reaction
condit
appli
modif
final
strategi
gener
apc
target
lv
base
fact
bind
fusion
function
lv
separ
two
distinct
glycoprotein
recent
exploit
concept
develop
dc
subtyp
specif
lv
pseudotyp
fusogen
bind
defect
glycoprotein
one
hand
apc
specif
transmembranari
nanobodi
hand
briefli
demonstr
cdc
also
pdc
macrophag
specif
transduct
human
subset
ex
vivo
murin
subset
vivo
importantli
similar
report
et
al
use
mhcii
target
approach
show
intranod
administr
dc
target
lv
enhanc
tcell
prolifer
without
function
therapeut
benefit
compar
untarget
lv
note
besid
viral
vector
also
bacteri
deriv
vector
enzym
success
use
target
taa
dc
subsequ
matur
induct
strong
antitumor
immun
summari
enorm
amount
studi
perform
evid
ad
valu
dc
target
antitumor
vaccin
howev
receptor
dcsign
receptor
mhcii
molecul
truli
specif
one
particular
apc
subset
subsequ
describ
intern
antigen
differ
dc
subset
differ
apc
subset
even
nonapc
endotheli
cell
thymic
epitheli
cell
hamper
evalu
dc
subtyp
specif
impact
induc
immun
respons
addit
sever
conflict
report
made
mous
versu
human
relat
studi
use
homolog
target
moieti
exampl
target
robust
ctl
respons
induc
mice
robust
humor
moder
tcell
respons
observ
adenocarcinoma
patient
addit
difficult
compar
differ
apc
target
studi
sinc
perform
differ
vaccin
moieti
differ
size
surfac
charg
differ
dose
diversifi
formul
target
approach
result
complet
differ
pharmacokinet
immunolog
outcom
therefor
urgent
need
defin
true
mean
dc
subset
specif
target
serv
understand
potent
activ
vaccin
antitumor
immun
although
numer
studi
evalu
confirm
efficaci
dc
subtyp
specif
target
immunotherapeut
purpos
studi
question
improv
compar
untarget
deliveri
therefor
want
elabor
section
true
mean
dc
subtyp
specif
target
activ
antitumor
vaccin
first
question
realli
possibl
target
apc
activ
alreadi
special
uptak
whatev
antigen
encount
kreutz
et
al
inject
abantigenadjuv
conjug
footpad
mice
preferenti
uptak
apc
mediat
expos
antigen
deriv
peptid
cpg
nucleic
acid
rather
apcspecif
ab
also
np
decor
mannosyl
algin
differ
dc
specif
target
ab
decor
less
influenti
murin
dc
specif
particl
uptak
respect
furthermor
similar
observ
made
group
nake
mrna
shown
intranod
deliveri
mainli
dc
involv
uptak
form
passiv
apc
target
evidenc
observ
noninfecti
lv
abl
induc
similar
therapeut
benefit
tumor
model
apc
target
lv
intranod
deliveri
latter
explain
uptak
protein
contamin
present
within
noninfecti
lv
prepar
presum
taken
apc
nontarget
fashion
notabl
demonstr
apc
target
lv
outperform
noninfecti
lv
term
tcell
stimul
suggest
activ
apc
target
factor
account
better
dc
activ
passiv
uptak
noninfecti
lv
contrast
dc
receptor
intern
paramet
investig
well
impact
antigen
present
outcom
target
turn
respons
antigen
present
ab
target
vaccin
vivo
analyz
endocytosi
vitro
show
neither
receptor
express
level
speed
receptor
intern
proport
surfac
turnov
antigen
load
impact
mhci
ii
mediat
antigen
present
contrari
dc
target
enhanc
mhcii
mediat
antigen
present
respect
therefor
conclud
receptor
express
level
speed
intern
andor
amount
antigen
deliv
could
exclud
major
determin
antigen
present
effici
set
ab
target
vaccin
one
eleg
approach
receptor
upregul
prior
target
investig
target
cancer
vaccin
compos
mab
fuse
oncofet
protein
show
humor
respons
low
vaccin
dose
could
enhanc
prior
administr
gmcsf
upregul
express
human
mannos
receptor
transgen
mice
coadministr
tlr
agonist
requir
elicit
immun
howev
prior
administr
gmcsf
one
could
question
express
overal
amount
apc
enhanc
situ
studi
conclud
activ
apc
target
still
debat
studi
warrant
unravel
enigma
practic
point
view
hypothes
apc
target
deliveri
vaccin
could
reduc
dose
requir
herebi
one
distinguish
two
concept
apc
specif
target
result
increas
uptak
vaccin
case
otherwis
nake
molecul
apc
specif
target
detarget
vaccin
deliveri
nonapc
case
infecti
agent
viral
vector
apc
specif
uptak
enhanc
gener
result
drastic
reduc
dose
requir
contrari
evalu
ctl
induc
capac
broad
tropism
versu
dc
target
lv
encod
ova
could
demonstr
substanti
benefit
dc
target
lv
broad
tropism
lv
term
dose
requir
without
loss
efficaci
anoth
strike
observ
made
compar
differ
dose
situ
deliv
target
versu
untarget
infecti
nonrepl
ovaencod
adenovir
vector
target
deliveri
outperform
untarget
deliveri
low
dose
administr
effector
cell
induc
high
dose
untarget
vaccin
compar
target
deliveri
interestingli
protect
capac
nontarget
vaccin
superior
target
vaccin
tumor
challeng
model
demonstr
dosedepend
effect
dc
target
qualiti
induc
immun
respons
term
safeti
vaccin
detarget
nonimmunogen
stromal
cell
could
reduc
risk
advers
reaction
develop
autoimmun
induct
toler
unwant
system
cytokin
releas
due
overstimul
inde
target
deliveri
tlr
agonist
reduc
dose
requir
associ
decreas
serum
cytokin
storm
relat
toxic
vivo
compar
administr
solubl
adjuv
furthermor
apc
target
potenti
reduc
risk
insert
mutagenesi
dna
lvbase
vaccin
directli
administ
sinc
apc
differenti
shortliv
cell
unlik
transform
malign
cell
next
apc
subtyp
specif
target
believ
allow
induct
specif
finetun
immun
respons
sinc
disentangl
heterogen
differ
apc
subtyp
specif
target
pave
way
toward
fundament
research
exact
therapeut
role
apc
subset
antitumor
immunotherapi
moreov
dc
subtyp
specif
target
alreadi
report
murinehuman
murin
human
pdc
siglech
murin
pdc
langerin
lc
show
promis
differ
elicit
immun
respons
reflect
specif
function
dc
subtyp
situ
howev
dc
subset
specif
function
fix
vari
among
sever
factor
speci
inflammatori
state
exemplifi
presum
favor
target
antitumor
vaccin
profession
crosspres
subset
peculiarli
equip
crosspres
antigen
dead
cell
seem
equal
potent
crosspres
solubl
antigen
compar
dc
subtyp
note
mice
subset
repres
main
produc
popul
human
product
limit
subset
importantli
lymphoid
tissu
nonlymphoid
tissu
dc
also
mediat
system
intestin
toler
respect
thu
lineag
respond
local
microenviron
order
induc
either
toler
crosspresent
depend
tcell
immun
line
observ
human
dc
equival
murin
cdc
also
shown
excel
crosspres
antigen
one
hand
suppress
immun
respons
hand
secret
induc
treg
nevertheless
specif
target
approach
appear
potent
erad
establish
melanoma
interestingli
howev
also
shown
coupl
polyi
c
curdlan
noth
vaccin
abl
modul
cell
treg
respect
suggest
embed
adjuv
vaccin
decis
immunolog
outcom
cell
type
specif
receptor
toward
target
final
target
believ
enhanc
vaccin
immun
stimulatori
potenti
sinc
detarget
taa
nonapc
also
b
cell
macrophag
could
avoid
induct
toler
rapid
antigen
degrad
inde
mice
treat
ova
coupl
fuse
ab
effici
potent
respons
measur
compar
untarget
antigen
furthermor
sever
preclin
clinic
trial
demonstr
effect
apc
target
vaccin
human
immunotherapi
summar
elsewher
howev
studi
evalu
target
antitumor
vaccin
base
target
receptor
mannos
receptor
see
tabl
specif
express
one
particular
dc
subset
therefor
hard
draw
conclus
regard
enhanc
effici
antitumor
immun
upon
exclus
target
one
dc
subset
moreov
target
cdc
alon
also
pdc
macrophag
use
nanobodi
display
lv
encod
ova
observ
clear
differ
induc
tcell
profil
therapeut
outcom
cdc
cdc
well
pdc
target
vaccin
compar
importantli
less
strong
broad
tropism
lv
vaccin
furthermor
question
target
respons
increas
immunogen
compar
untarget
deliveri
sinc
increas
also
ascrib
immunomodul
role
target
moieti
less
target
specif
dc
subset
base
current
knowledg
strong
rational
target
one
dc
subset
anoth
prime
taa
specif
ctl
addit
vivo
studi
human
dc
subset
specif
target
definit
need
identifi
special
dc
subset
rational
signifi
report
bystand
matur
cdc
pdc
well
need
multipl
dc
subset
activ
optim
effector
tcell
immun
exemplifi
studi
combin
dcsign
target
np
superior
target
either
subset
alon
term
tcell
activ
mechan
underli
observ
synergi
involv
dcdc
cross
talk
suggest
target
one
apc
subset
could
depriv
result
immun
respons
benefit
cross
talk
differ
dc
subset
therefor
upcom
treatment
paradigm
aim
includ
sever
primari
dc
subset
singl
vaccin
preclin
studi
identifi
synergist
effect
variou
apc
overload
target
vaccin
studi
demonstr
vaccin
tailormad
induc
particular
phenotyp
adapt
immun
specif
target
differ
surfac
molecul
dc
subset
nonetheless
conflict
result
regard
outcom
target
vaccin
induc
therapeut
antitumor
immun
also
stress
benefit
target
may
overestim
immunogen
everi
vaccin
irrespect
target
abil
also
character
dose
size
surfac
charg
cargo
presenc
adjuv
rout
administr
speci
deliv
question
remain
one
target
omnipot
dc
subtyp
realli
exist
increas
effici
current
antitumor
vaccin
strategi
